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Role of cAMP- phosphodiesterases in submembrane beta- adrenergic 
cAMP signals in cultured adult rat aortic smooth muscle cells
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This study investigated the role of cyclic nucleotide phosphodiesterases 
(PDEs) in the spatiotemporal control of intracellular cAMP concentrations 
in vascular smooth muscle cells. β- adrenergic receptors stimulation leads to 
an intracellular compartmentation of cAMP resulting from localized cyclic 
nucleotide phosphodiesterase (PDE) activity. Rat aortic smooth muscle cells 
(RASMC) were isolated from adult male Wistar rats, cultured and used under 
a synthetic phenotype.
To evaluate the time course of the cAMP changes at the plasma mem-
brane, brief (15 seconds) pulses of isoproterenol (10- 100 nM) were applied 
to RASMC monitoring cAMP changes beneath the membrane using the À uo-
rescence resonance energy transfer- based sensor, Lyn- Epac2B. A brief pulse 
(15s) of isoproterenol (100 nM) induced a typical FRET signal, increasing 
to a maximum of ~22%, before returning to baseline with a t1/2off of 107s. 
Whereas CGP 20712A (a β1- AR antagonist, 100 nM) had no effect on the 
amplitude of isoproterenol response, ICI 118551 (a β2- AR antagonist, 5 nM) 
strongly decreased it, indicating that only β2- ARs are involved in this res-
ponse. The non- selective PDE inhibitor, 3- isobutyl- 1- methylxanthine (100 M 
IBMX), dramatically increased the amplitude and delayed the onset and reco-
very phase of isoproterenol response (10 nM), in agreement with a role of 
PDEs in degrading cAMP produced by isoproterenol. PDE3 and PDE4 bloc-
kades [with 1 M cilostamide, and 10 M Ro- 20- 1724, respectively] strongly 
increased the amplitude of isoproterenol response by 47% and 33% respecti-
vely. Cilostamide delayed recovery of cAMP transients by 85% and Ro- 20- 
1724 by 158%. When PDE3 and PDE4 inhibitors were applied concomitantly, 
the isoproterenol response was drastically further prolonged in duration.
Our study underlines the importance of cAMP- PDEs for the spatiotem-
poral control of submembrane cAMP signals in synthetic RASMCs, and 
demonstrates the prominent role of PDE3 and PDE4 in limiting β- adrenergic 
responses.
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MiR- 424/322 regulates proliferation in vascular smooth muscle cells
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We performed a microarray analysis to identify new miRNA modulated 
during proliferation of human vascular smooth muscle cells (VSMC). Among 
several miRNA differentially expressed, we focused on miR- 424 (ortholo-
gous to rat miR- 322) because its predicted targets included pro- proliferative 
cyclin D1 and calumenin, a protein implicated in Ca2+ signaling which inhi-
bits SERCA2a activity. MiR- 424/322 expression was at ¿ rst decreased in 
VSMC after serum- induced proliferation but then increased signi¿ cantly 
after 72 hours. Similarly in vivo its expression increased 4 days after balloon- 
angioplasty of rat carotid artery and miR- 322 stayed highly upregulated for at 
least 30 days. MiR- 322 overexpression by Pre- miR322 transfection (Ambion, 
Life Technologies) inhibited proliferation by 35% and induced expression of 
differentiation markers smooth muscle alpha actin and calponin in VSMC 
after 48 hours. As shown by Western- Blot, miR- 322 predicted targets cyclin 
D1 and calumenin were signi¿ cantly decreased. By cloning cyclin D1 or calu-
menin 3’UTR in a luciferase expression vector, we then con¿ rmed that cyclin 
D1 and calumenin mRNA are directly targeted by miR- 322.
All these ¿ ndings point towards an anti- proliferative role of miR- 424/322 
in the vessel. To study the effect of miR- 322 overexpression on restenosis, we 
now have produced an adenovirus overexpressing miR- 322 (Ad- 322) which 
allows 50 fold induction after 4 days. Left- carotid arteries will be infused with 
Ad- 322 or a control adenovirus without effect (Ad- shNeg) after balloon angio-
plasty in the rat and neointima formation will be analyzed after 14 days.
0146
Identi¿ cation of new modulators of PGC- 1α expression in a cardiac- 
like cell line by a robotized cellular and molecular assay
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Heart failure (HF) is a complex clinical syndrome resulting from the inabi-
lity of the cardiac pump to meet the energy requirements of the body. Cardiac 
energetic charge is a predictive factor of mortality rate in patients with dilated 
cardiomyopathy. Mitochondrial function is dramatically altered in HF and 
associated with a decrease in the transcriptional coactivator PGC- 1α expres-
sion, known as a potent regulator of energy metabolism, in particular oxidative 
phosphorylation and mitochondrial biogenesis. We hypothesized that PGC- 1α 
could be a new therapeutic target to overcome energetic de¿ ciency in HF.
We have developed a miniaturized cellular test based on the expression 
of a secreted luciferase under the control of the human PGC- 1α promoter, 
stably expressed in a cardiac- like cell line (H9c2). In order to discover new 
regulation pathways we have screened a library of human endogenous ligands 
(GreenPharma).
Our results allowed identifying three families of ligands able to activate the 
expression of PGC- 1α: steroid hormones, vitamins B and fatty acids and were 
con¿ rmed in a dose- dependent manner. The most representative compounds 
of these families were also tested by measuring endogenous PGC- 1α gene 
expression on adult rat cardiomyocytes.
These data highly con¿ rmed previous screening results and the increase in 
PGC- 1α mRNA expression correlated with an increase in several markers of 
mitochondrial biogenesis like NRF2, ERRα, TFAM and COXI. Moreover, res-
piration rates of H9c2 cell line treated with these compounds were increased 
showing a bene¿ t in oxidative capacity. 
We identi¿ ed three original families, able to activate mitochondrial bioge-
nesis both in cell line and adult cardiomyocytes. Signal transduction pathway 
remains to be determined. This ¿ rst screening will be extended to other che-
mical libraries in order to increase our knowledge on PGC- 1α regulation in 
heart and identify a potential therapeutic compound improving mitochondrial 
function in HF.
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